BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:BSX • US1011371077

66 EUR
+0.4 (+0.61%)
Last: Feb 5, 2026, 07:00 PM
Fundamental Rating

5

Overall BSX gets a fundamental rating of 5 out of 10. We evaluated BSX against 68 industry peers in the Health Care Equipment & Supplies industry. BSX scores excellent on profitability, but there are some minor concerns on its financial health. BSX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year BSX was profitable.
  • BSX had a positive operating cash flow in the past year.
  • BSX had positive earnings in 4 of the past 5 years.
  • BSX had a positive operating cash flow in each of the past 5 years.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • The Return On Assets of BSX (6.54%) is better than 75.00% of its industry peers.
  • With a decent Return On Equity value of 11.93%, BSX is doing good in the industry, outperforming 72.06% of the companies in the same industry.
  • The Return On Invested Capital of BSX (8.09%) is better than 70.59% of its industry peers.
  • BSX had an Average Return On Invested Capital over the past 3 years of 6.59%. This is below the industry average of 9.62%.
  • The last Return On Invested Capital (8.09%) for BSX is above the 3 year average (6.59%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROIC 8.09%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

  • The Profit Margin of BSX (14.42%) is better than 83.82% of its industry peers.
  • BSX's Profit Margin has declined in the last couple of years.
  • BSX has a better Operating Margin (19.40%) than 82.35% of its industry peers.
  • In the last couple of years the Operating Margin of BSX has remained more or less at the same level.
  • BSX's Gross Margin of 68.57% is fine compared to the rest of the industry. BSX outperforms 77.94% of its industry peers.
  • In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
Industry RankSector Rank
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, BSX has more shares outstanding
  • BSX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BSX is higher compared to a year ago.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • An Altman-Z score of 4.57 indicates that BSX is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.57, BSX is in the better half of the industry, outperforming 79.41% of the companies in the same industry.
  • BSX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as BSX would need 3.03 years to pay back of all of its debts.
  • BSX's Debt to FCF ratio of 3.03 is fine compared to the rest of the industry. BSX outperforms 75.00% of its industry peers.
  • A Debt/Equity ratio of 0.48 indicates that BSX is not too dependend on debt financing.
  • BSX has a Debt to Equity ratio (0.48) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Altman-Z 4.57
ROIC/WACC0.82
WACC9.86%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

  • BSX has a Current Ratio of 1.51. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.51, BSX perfoms like the industry average, outperforming 45.59% of the companies in the same industry.
  • A Quick Ratio of 0.96 indicates that BSX may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.96, BSX perfoms like the industry average, outperforming 41.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 0.96
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
  • The Earnings Per Share has been growing by 9.56% on average over the past years. This is quite good.
  • The Revenue has grown by 21.62% in the past year. This is a very strong growth!
  • BSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.30% yearly.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%

3.2 Future

  • Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.06% on average per year.
  • The Revenue is expected to grow by 12.60% on average over the next years. This is quite good.
EPS Next Y22.12%
EPS Next 2Y18.13%
EPS Next 3Y16.37%
EPS Next 5Y15.06%
Revenue Next Year20.92%
Revenue Next 2Y16.08%
Revenue Next 3Y14.31%
Revenue Next 5Y12.6%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 26.40, BSX can be considered very expensive at the moment.
  • 60.29% of the companies in the same industry are more expensive than BSX, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.67. BSX is around the same levels.
  • BSX is valuated rather expensively with a Price/Forward Earnings ratio of 22.23.
  • BSX's Price/Forward Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.20, BSX is valued at the same level.
Industry RankSector Rank
PE 26.4
Fwd PE 22.23
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSX indicates a slightly more expensive valuation: BSX is more expensive than 66.18% of the companies listed in the same industry.
  • BSX's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 30.19
EV/EBITDA 24.63
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of BSX may justify a higher PE ratio.
  • A more expensive valuation may be justified as BSX's earnings are expected to grow with 16.37% in the coming years.
PEG (NY)1.19
PEG (5Y)2.76
EPS Next 2Y18.13%
EPS Next 3Y16.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BOSTON SCIENTIFIC CORP

FRA:BSX (2/5/2026, 7:00:00 PM)

66

+0.4 (+0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-22
Earnings (Next)02-04
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap97.84B
Revenue(TTM)19.35B
Net Income(TTM)2.79B
Analysts85.5
Price Target108.94 (65.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-0.14%
PT rev (3m)-1.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.01%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.76%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.13%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)1%
Valuation
Industry RankSector Rank
PE 26.4
Fwd PE 22.23
P/S 5.97
P/FCF 30.19
P/OCF 24.96
P/B 4.93
P/tB N/A
EV/EBITDA 24.63
EPS(TTM)2.5
EY3.79%
EPS(NY)2.97
Fwd EY4.5%
FCF(TTM)2.19
FCFY3.31%
OCF(TTM)2.64
OCFY4.01%
SpS11.06
BVpS13.38
TBVpS-1.13
PEG (NY)1.19
PEG (5Y)2.76
Graham Number27.43
Profitability
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROCE 10.04%
ROIC 8.09%
ROICexc 8.38%
ROICexgc 28.19%
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
FCFM 19.76%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Debt/EBITDA 2.18
Cap/Depr 59.36%
Cap/Sales 4.14%
Interest Coverage 250
Cash Conversion 90.6%
Profit Quality 136.98%
Current Ratio 1.51
Quick Ratio 0.96
Altman-Z 4.57
F-Score6
WACC9.86%
ROIC/WACC0.82
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y22.12%
EPS Next 2Y18.13%
EPS Next 3Y16.37%
EPS Next 5Y15.06%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year20.92%
Revenue Next 2Y16.08%
Revenue Next 3Y14.31%
Revenue Next 5Y12.6%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year37.52%
EBIT Next 3Y20.65%
EBIT Next 5Y17.42%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%

BOSTON SCIENTIFIC CORP / BSX.DE FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.


How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 7 / 10.


What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 26.4 and the Price/Book (PB) ratio is 4.93.


Can you provide the expected EPS growth for BSX stock?

The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 22.12% in the next year.